Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo

References

• Owen JL, Sahay B, Mohamadzadeh M. New generation of oral mucosal vaccines targeting dendritic cells. Curr Opin Chem Biol. 2013;17(6):918–924. doi:10.1016/j.cbpa.2013.06.013
   PubMed Web of Science ®Google Scholar
• Moll H. Dendritic cells and host resistance to infection. Cell Microbiol. 2003;5(8):493–500. doi:10.1046/j.1462-5822.2003.00291.x
   PubMed Web of Science ®Google Scholar
• Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, Britton WJ. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol. 2005;42(8):979–985. doi:10.1016/j.molimm.2004.09.034
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7(10):790–802. doi:10.1038/nri2173
   PubMed Web of Science ®Google Scholar
• Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol. 2012;33(2):71–77. doi:10.1016/j.it.2011.10.007
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv. 2013;2013:869718. doi:10.1155/2013/869718
   PubMedGoogle Scholar
• Keler T, He L, Ramakrishna V, Champion B. Antibody-targeted vaccines. Oncogene. 2007;26(25):3758–3767. doi:10.1038/sj.onc.1210375
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–277. doi:10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials. 2012;33(16):4229–4239. doi:10.1016/j.biomaterials.2012.02.036
   PubMed Web of Science ®Google Scholar
• Chen P, Liu X, Sun Y, Zhou P, Wang Y, Zhang Y. Dendritic cell targeted vaccines: recent progresses and challenges. Hum Vaccin Immunother. 2016;12(3):612–622. doi:10.1080/21645515.2015.1105415
   PubMed Web of Science ®Google Scholar
• Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008;1786(2):126–138. doi:10.1016/j.bbcan.2008.03.001
   PubMed Web of Science ®Google Scholar
• Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc Natl Acad Sci U S A. 2009;106(11):4331–4336. doi:10.1073/pnas.0900029106
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Hill AV. Prime-boost strategies for malaria vaccine development. J Exp Biol. 2003;206(Pt 21):3771–3779. doi:10.1242/jeb.00642
   PubMed Web of Science ®Google Scholar
• Wang YP, Liu D, Guo LJ, et al. Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-gamma in mice. Vaccine. 2013;31(5):833–838. doi:10.1016/j.vaccine.2012.11.062
   PubMed Web of Science ®Google Scholar
• Mao Q, Zhang W, Ma S, et al. Fusion expression and immune effect of PCV2 cap protein tandem multiantigen epitopes with CD154/GM-CSF. Vet Sci. 2021;8(10). doi:10.3390/vetsci8100211
   PubMed Web of Science ®Google Scholar
• Chang XX, Fan K, Meng W, et al. Truncated diphtheria toxin DT390 enhances the humoral immunogenicity of porcine circovirus Type 2 capsid antigen in mice. Viral Immunol. 2021;34(7):448–456. doi:10.1089/vim.2020.0339
   PubMed Web of Science ®Google Scholar
• Wu PC, Lin WL, Wu CM, Chi JN, Chien MS, Huang C. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development. Appl Microbiol Biotechnol. 2012;95(6):1501–1507. doi:10.1007/s00253-012-4015-2
   PubMed Web of Science ®Google Scholar
• Xi X, Mo X, Xiao Y, et al. Production of Escherichia coli-based virus-like particle vaccine against porcine circovirus type 2 challenge in piglets: structure characterization and protective efficacy validation. J Biotechnol. 2016;223:8–12. doi:10.1016/j.jbiotec.2016.02.025
   PubMed Web of Science ®Google Scholar
• Liu X, Liu Y, Zhang Y, Zhang F, Du E. Incorporation of a truncated form of flagellin (TFlg) into porcine circovirus type 2 virus-like particles enhances immune responses in mice. BMC Vet Res. 2020;16(1):45. doi:10.1186/s12917-020-2253-6
   PubMed Web of Science ®Google Scholar
• Li W, Wang X, Bai J, et al. Construction and immunogenicity of recombinant porcine circovirus-like particles displaying somatostatin. Vet Microbiol. 2013;163(1–2):23–32. doi:10.1016/j.vetmic.2012.11.045
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–132. doi:10.1016/j.smim.2017.08.014
   PubMed Web of Science ®Google Scholar
• Silva AL, Rosalia RA, Varypataki E, Sibuea S, Ossendorp F, Jiskoot W. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. Vaccine. 2015;33(7):847–854. doi:10.1016/j.vaccine.2014.12.059
   PubMed Web of Science ®Google Scholar
• Li X, Meng X, Wang S, et al. Virus-like particles of recombinant PCV2b carrying FMDV-VP1 epitopes induce both anti-PCV and anti-FMDV antibody responses. Appl Microbiol Biotechnol. 2018;102(24):10541–10550. doi:10.1007/s00253-018-9361-2
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Morris C, Brumlik M, et al. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol. 2004;172(12):7425–7431. doi:10.4049/jimmunol.172.12.7425
   PubMed Web of Science ®Google Scholar
• Ye C, Choi JG, Abraham S, Shankar P, Manjunath N. Targeting DNA vaccines to myeloid cells using a small peptide. Eur J Immunol. 2015;45(1):82–88. doi:10.1002/eji.201445010
   PubMed Web of Science ®Google Scholar
• Ye C, Choi JG, Abraham S, et al. Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci U S A. 2012;109(51):21052–21057. doi:10.1073/pnas.1216195109
   PubMed Web of Science ®Google Scholar
• Liu ZH, Xu HL, Han GW, et al. Self-assembling nanovaccine enhances protective efficacy against CSFV in pigs. Front Immunol. 2021;12:689187. doi:10.3389/fimmu.2021.689187
   PubMed Web of Science ®Google Scholar
• Marcekova Z, Psikal I, Kosinova E, Benada O, Sebo P, Bumba L. Heterologous expression of full-length capsid protein of porcine circovirus 2 in Escherichia coli and its potential use for detection of antibodies. J Virol Methods. 2009;162(1–2):133–141. doi:10.1016/j.jviromet.2009.07.028
   PubMed Web of Science ®Google Scholar
• Fort M, Olvera A, Sibila M, Segales J, Mateu E. Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. Vet Microbiol. 2007;125(3–4):244–255. doi:10.1016/j.vetmic.2007.06.004
   PubMed Web of Science ®Google Scholar
• Meng XJ. Porcine circovirus type 2 (PCV2): pathogenesis and interaction with the immune system. Annu Rev Anim Biosci. 2013;1:43–64. doi:10.1146/annurev-animal-031412-103720
   PubMed Web of Science ®Google Scholar
• Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95. doi:10.1038/cr.2016.157
   PubMed Web of Science ®Google Scholar
• Ueno H, Klechevsky E, Schmitt N, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011;23(1):21–27. doi:10.1016/j.smim.2011.01.004
   PubMed Web of Science ®Google Scholar
• Sehgal K, Dhodapkar KM, Dhodapkar MV. Targeting human dendritic cells in situ to improve vaccines. Immunol Lett. 2014;162(1Pt A):59–67. doi:10.1016/j.imlet.2014.07.004
   PubMed Web of Science ®Google Scholar
• Dubensky TJ, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22(3):155–161. doi:10.1016/j.smim.2010.04.007
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503. doi:10.1016/j.immuni.2010.10.002
   PubMed Web of Science ®Google Scholar
• McCullough KC, Summerfield A. Targeting the porcine immune system–particulate vaccines in the 21st century. Dev Comp Immunol. 2009;33(3):394–409. doi:10.1016/j.dci.2008.07.015
   PubMed Web of Science ®Google Scholar
• Ding P, Zhang G, Chen Y, et al. Reasonable permutation of M2e enhances the effect of universal influenza nanovaccine. Int J Biol Macromol. 2021;173:244–250. doi:10.1016/j.ijbiomac.2021.01.132
   PubMed Web of Science ®Google Scholar
• Wang N, Zhang Y, Lei X, et al. Optimized conditions for preserving stability and integrity of porcine circovirus type2 virus-like particles during long-term storage. J Virol Methods. 2017;243:146–150. doi:10.1016/j.jviromet.2017.01.021
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–252. doi:10.1038/32588
   PubMed Web of Science ®Google Scholar
• Liu ZH, Xu HL, Han GW, et al. A self-assembling nanoparticle: implications for the development of thermostable vaccine candidates. Int J Biol Macromol. 2021;183:2162–2173. doi:10.1016/j.ijbiomac.2021.06.024
   PubMed Web of Science ®Google Scholar
• Chiang CY, Chen YJ, Wu CC, Liu SJ, Leng CH, Chen HW. Efficient uptake of recombinant lipidated survivin by antigen-presenting cells initiates antigen cross-presentation and antitumor immunity. Front Immunol. 2018;9:822. doi:10.3389/fimmu.2018.00822
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306. doi:10.1038/nri1592
   PubMed Web of Science ®Google Scholar
• Lakhrif Z, Moreau A, Herault B, et al. Targeted delivery of toxoplasma gondii antigens to dendritic cells promote immunogenicity and protective efficiency against toxoplasmosis. Front Immunol. 2018;9:317. doi:10.3389/fimmu.2018.00317
   PubMed Web of Science ®Google Scholar
• Yang J, Sakai J, Siddiqui S, et al. IL-6 impairs vaccine responses in neonatal mice. Front Immunol. 2018;9:3049. doi:10.3389/fimmu.2018.03049
   PubMed Web of Science ®Google Scholar
• Ballesteros-Tato A, Randall TD. Priming of T follicular helper cells by dendritic cells. Immunol Cell Biol. 2014;92(1):22–27. doi:10.1038/icb.2013.62
   PubMed Web of Science ®Google Scholar
• Hannestad K, Scott H. A nonadjuvanted IgG2a monoclonal antibody against nucleosomes elicits potent T cell-dependent, idiotype-specific IgG1 responses and glomerular IgG1/IgG2a deposits in normal mice. J Immunol. 2017;199(2):489–500. doi:10.4049/jimmunol.1600718
   PubMed Web of Science ®Google Scholar
• Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Immunol Res. 2020;68(6):325–339. doi:10.1007/s12026-020-09159-z
   PubMed Web of Science ®Google Scholar
• Fu C, Zhou L, Mi QS, Jiang A. DC-based vaccines for cancer immunotherapy. Vaccines. 2020;8(4). doi:10.3390/vaccines8040706
   Web of Science ®Google Scholar
• Dimeloe S, Burgener AV, Grahlert J, Hess C. T-cell metabolism governing activation, proliferation and differentiation; a modular view. Immunology. 2017;150(1):35–44. doi:10.1111/imm.12655
   PubMed Web of Science ®Google Scholar
• Heinzel S, Marchingo JM, Horton MB, Hodgkin PD. The regulation of lymphocyte activation and proliferation. Curr Opin Immunol. 2018;51:32–38. doi:10.1016/j.coi.2018.01.002
   PubMed Web of Science ®Google Scholar
• Xu X, Huang H, Wang Q, et al. IFN-gamma-producing Th1-like regulatory T cells may limit acute cellular renal allograft rejection: paradoxical post-transplantation effects of IFN-gamma. Immunobiology. 2017;222(2):280–290. doi:10.1016/j.imbio.2016.09.012
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Gu W, Sun B. Erratum to: th1/Th2 cell differentiation and molecular signals. Adv Exp Med Biol. 2014;841:E1–2.
   PubMed Web of Science ®Google Scholar
• Coomes SM, Kannan Y, Pelly VS, et al. CD4(+) Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal Immunol. 2017;10(1):150–161. doi:10.1038/mi.2016.47
   PubMed Web of Science ®Google Scholar
• Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol. 2009;183(8):4904–4912. doi:10.4049/jimmunol.0900284
   PubMed Web of Science ®Google Scholar
• Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med. 1996;183(5):2361–2366. doi:10.1084/jem.183.5.2361
   PubMed Web of Science ®Google Scholar
• Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002;111(7):927–930. doi:10.1016/S0092-8674(02)01201-1
   PubMed Web of Science ®Google Scholar
• Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev. 2004;199:227–250. doi:10.1111/j.0105-2896.2004.00144.x
   PubMed Web of Science ®Google Scholar
• Ma S, Qiao X, Xu Y, et al. Screening and identification of a chicken dendritic cell binding peptide by using a phage display library. Front Immunol. 2019;10:1853. doi:10.3389/fimmu.2019.01853
   PubMed Web of Science ®Google Scholar
• Agnew HD, Coppock MB, Idso MN, et al. Protein-Catalyzed Capture Agents. Chem Rev. 2019;119(17):9950–9970. doi:10.1021/acs.chemrev.8b00660
   PubMed Web of Science ®Google Scholar
• Chan KH, Lim J, Jee JE, Aw JH, Lee SS. Peptide-peptide co-assembly: a design strategy for functional detection of C-peptide, A biomarker of diabetic neuropathy. Int J Mol Sci. 2020;21(24):9671. doi:10.3390/ijms21249671
   PubMed Web of Science ®Google Scholar